Please assess the completion status of the following clinical trial:

Trial Title: Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.~Inclusion Criteria:~* Documented progression from most recent line of therapy~* Measurable disease~* 1 to 3 prior lines of therapy~  * Subjects may be proteasome inhibitor naive or have received prior proteasome inhibitor therapy provided all the following criteria are met:~    1. The subject did not discontinue any proteasome inhibitor due to intolerance or grade ≥ 3 toxicity~   2. The subject is not refractory to any proteasome inhibitor, defined as progression during treatment or within 60 days after the last dose~   3. The subject previously achieved a partial response (PR) or better to previous proteasome inhibitor (PI)~Exclusion Criteria:~* Monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, or Waldenstrom's macroglobulinemia~* Active plasma cell leukemia~* Known Human immunodeficiency virus (HIV) infection or active hepatitis A, B, or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Elotuzumab + Bortezomib + Dexamethasone (Type: EXPERIMENTAL): On days of Elotuzumab infusion: Dexamethasone (8mg IV + 8mg Oral) will be administered other days Dexamethasone 20 mg Oral will be administered
- Arm B: Bortezomib + Dexamethasone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).